by Ulcerative colitis is a chronic disease that causes long-lasting inflammation and ulcers in the lining of the large intestine or rectum. The disease typically affects the rectum and lower colon but in some cases can spread further up. Key symptoms of ulcerative colitis include abdominal pain, rectal bleeding, bloody diarrhea, frequent bowel movements and urgency. Biologics and immunosuppressants are primarily used for treatment of moderate to severe cases of ulcerative colitis.
The Global United Kingdom Ulcerative Colitis Market Size is estimated to be valued at US$ 421.3 Mn in 2024 and is expected to exhibit a CAGR of 3.4% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the United Kingdom ulcerative colitis are AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson and Among Others. The rising prevalence of ulcerative colitis in the UK is creating growth opportunities for players in the form of new product development and geographical expansion. Market players are expanding their presence through collaborations with healthcare providers as well as research institutes for conducting clinical trials to develop new advanced treatment options for ulcerative colitis. With favorable government support and reimbursement policies, major players are looking at the UK as an important market for global expansion of their ulcerative colitis treatment portfolio.
Market Drivers
The key driver for the growth of ulcerative colitis market in the UK is increasing disease prevalence. According to Crohn’s & Colitis UK, over 146,000 people in the UK suffer from ulcerative colitis. There is no known cause for the disease and the exact cause is still unknown. However, factors such as family history, smoking and immune system abnormalities are associated with increased risk. Rising awareness about the disease and its treatment options is also expected to boost the demand for ulcerative colitis drugs in the country.
PEST Analysis
Political: The government regulates drug approval and healthcare policies that can impact the market. Changes in regulations may affect market growth positively or negatively.
Economic: The overall economy and GDP growth impacts healthcare spending. Recession can reduce expenditures on non-essential treatments like UC drugs. High cost of biologics also affects market demand.
Social: Rising incidence of ulcerative colitis due to changes in lifestyle and diet is driving market growth. Growing health awareness and screenings are also supporting early detection and treatment adoption.
Technological: Development of novel drug delivery systems, biomarker based diagnostics, and personalized medicine approaches are improving treatment effectiveness. Biosimilars market expansion is making drugs affordable to more patients.
United Kingdom accounts for the largest share of the market in Europe. Factors such as favorable reimbursement policies, availability of advanced healthcare facilities, and growing physician awareness are fueling market growth in the country. Germany and France hold the second and third position, respectively, due to strategic initiatives by manufacturers and rising research in inflammatory bowel disease.
The North American region is expected to witness the fastest growth during the forecast period. This is attributed to the presence of major players, increasing research funding for drug discovery, and expanding base of patients in the US and Canada. Rising healthcare expenditures and government support for novel technologies are stimulating market expansion in the region.
What Are The Key Data Covered In This United Kingdom Ulcerative Colitis Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the United Kingdom Ulcerative Colitis’s growth between 2024 and 2031.
:- Accurate calculation of the size of the United Kingdom Ulcerative Colitis and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- United Kingdom Ulcerative Colitis Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of United Kingdom Ulcerative Colitis vendors
FAQ’s
Q.1 What are the main factors influencing the United Kingdom Ulcerative Colitis?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top United Kingdom Ulcerative Colitis companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the United Kingdom Ulcerative Colitis’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
